Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacnotuzumab with carboplatin and gemcitabine in advanced TNBC
NCT02435680Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Primary completion
- Jan 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of lacnotuzumab in triple-negative breast cancer (TNBC), sponsored by Novartis. Started Aug 2015; status: completed.
02
Drugs
lacnotuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02435680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435680.